Physician profile
Robert John Holmes
NPI 1306803234
$4,651.91
in general payments reported to CMS, 2019-2025
41 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $482 · 2021: $63.62 · 2022: $493 · 2023: $1,050 · 2024: $872 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $661.58 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $579.09 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $461.25 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Fujifilm Healthcare Americas Corporation | $240.69 | 2020-2022 | |
| Gilead Sciences, INC. | $183.05 | 2019-2024 | |
| Pfizer INC. | $154.18 | 2019-2025 | |
| Celgene Corporation | $149.97 | 2020-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $96.84 | 2019-2024 | Dificid |
| Qol Medical, LLC | $89.95 | 2019-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $85.87 | 2020-2025 | Ocaliva |
| Organon LLC | $77.09 | 2022-2023 | Renflexis, Hadlima |
| Genzyme Corporation | $76.58 | 2023-2025 | |
| Ucb, INC. | $75.43 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $74.02 | 2022-2025 | Linzess |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $64.37 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $58.90 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $58.59 | 2025 | Voquezna |
| Redhill Biopharma INC. | $53.14 | 2023 | Talicia |
| Shionogi INC | $51.38 | 2019 | |
| Braintree Laboratories, INC. | $48.04 | 2022-2023 | Sutab, Suflave |
| Daiichi Sankyo INC. | $45.71 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $37.96 | 2022-2023 | Imjudo |
| Lilly USA, LLC | $29.83 | 2024-2025 | Omvoh |
| Shire North American Group INC | $28.14 | 2019 | |
| Intra-Sana Laboratories | $27.76 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Amgen INC. | $23.28 | 2020 | |
| Madrigal Pharmaceuticals | $21.67 | 2024 | Resmetirom |
| Mylan Institutional INC. | $19.76 | 2023 | Hulio |
| Nestle Healthcare Nutrition INC. | $19.59 | 2022 | |
| Exact Sciences Corporation | $18.38 | 2025 | The Cologuard Plus Collection Kit |
| Vivus LLC | $16.25 | 2025 | Pancreaze |
| Horizon Therapeutics Plc | $15.85 | 2023 | Krystexxa |
| Ferring Pharmaceuticals INC. | $14.99 | 2023 | Rebyota |
| Shield Therapeutics INC | $14.14 | 2023 | Accrufer |
| Invivyd INC | $13.53 | 2025 | Pemgarda |
| Allergan, INC. | $10.91 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.